このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Hypertension With Unsatisfactory Sleep Health (HUSH)

2020年9月1日 更新者:Daniel J. Buysse, M.D.、University of Pittsburgh

Pragmatic Trial of Behavioral Interventions for Insomnia in Hypertensive Patients

Insomnia and hypertension are common health problems that often occur together and influence each other. This practical, low-cost, clinical trial will evaluate two behavioral treatments for insomnia (a brief intervention with therapist contact and a self-guided Internet intervention) compared to usual care. Participants will be recruited using the electronic health record in their primary care physicians' offices, and will be evaluated for sleep, blood pressure, and health outcomes after 9 weeks, 6 months, and 12 months.

調査の概要

詳細な説明

Insomnia is a prevalent, chronic, and inadequately-treated chronic medical condition associated with comorbid conditions such as hypertension (HTN) and a range of adverse health outcomes. Hypnotic medications are efficacious and widely available, but they have potentially serious adverse effects. Patients and providers prefer non-drug treatments such as Cognitive-Behavioral Treatment of Insomnia (CBT-I), which is safe, efficacious, and durable-but not widely available. Innovative use of electronic health records (EHR) to identify patients, and the availability of new technologies that enable cognitive-behavioral interventions to be delivered at scale, with high treatment fidelity, and at low cost, offer exciting opportunities to address these critical problems. The investigators propose a low-cost, pragmatic, patient-centered, randomized controlled trial comparing two CBT-I-based interventions for insomnia with comorbid hypertension (INS+HTN) to primary care physicians' (PCP) enhanced usual care (EUC). The setting will be University of Pittsburgh Medical Center (UPMC) primary care practices. Participants will be 625 adults with INS+HTN. Recruitment will be conducted using alerts in the EpicCare EHR triggered by patient characteristics (hypertension; hypnotic medications or insomnia diagnosis/problem). The investigators will compare 3 interventions: Brief Behavioral Treatment of Insomnia (BBTI), involving electronic educational material and 4 telephone/web sessions with a live interventionist; "Sleep Healthy Using The Internet" (SHUTi), a self-guided, 8-module, Internet version of CBT-I, with no human contact; and EUC, which includes assessment and educational information for participants and providers. The primary outcome will be self-reported sleep at 9 weeks. Other outcomes include domains of symptoms, health, and patient/provider satisfaction obtained by self-report, home blood pressure monitoring (HBPM), and EHR. Specific Aims for the trial are: (1) To compare interventions on patient-reported symptoms at 9 weeks, 6 months, and 12 months. (2) To compare interventions on health indicators including self-report, HBPM, and EHR measures at 6 and 12 months. (3) To compare patient and provider-level satisfaction with the 3 interventions. (4) Exploratory Aim: To compare BBTI and CBT-I on each outcome domain and intervention adherence/drop-outs.

We made changes to the outcome measures document in April, 2019, and further amended these measures in June, 2019. The reason for these changes was to ensure consistency among the grant application, clinical trial protocol paper, and ClinicalTrials.gov. We made the following specific changes and corrections:

  • Insomnia diagnosis, cumulative illness rating scale, and treatment expectations were removed as secondary outcomes, as they are not listed in our protocol as outcome measures. They are only measured at baseline to characterize participants.
  • Health-Related Quality of Life "Medical Outcomes Survey Short Form-12 and Client Satisfaction "Client Satisfaction Questionnaire" were changed from primary to secondary outcome measures, to ensure consistency with the grant application and protocol paper.
  • Side effects "Treatment-related Side Effects Scale" were changed from a secondary to an "other" outcome measure, again to ensure consistency with the grant application and protocol paper.

The following outcome measures were added to ClinicalTrials.gov to ensure consistency:

Secondary Outcome: Provider Satisfaction "Provider Satisfaction Survey"

Other Prespecified Outcome Measures:

  • Daytime Impairment Related to Sleep "PROMIS Sleep Related Impairment"
  • Insomnia Severity "Insomnia Severity Index"
  • Sleep Quality "Pittsburgh Sleep Quality Index"
  • Daytime Sleepiness "Epworth Sleepiness Scale"
  • Falls "Side Effect/Falls Questionnaire" "Falls Follow-up Questionnaire"
  • Improvement "Patient Global Impression of Improvement Scale"
  • Sleep Diary Measures "HUSH Daily Diary"

We also recognized that we had erroneously interpreted "time frame" as the time frame of the instrument itself, rather than the time frame of the assessment battery. Time frames in ClinicalTrials.gov were corrected to capture the time points at which they are assessed, in the following measures:

  • Sleep disturbance "PROMIS Sleep Disturbance Scale"
  • Health related quality of life "Medical Outcomes Survey Short Form-12"
  • Client satisfaction "Client Satisfaction Questionnaire"
  • Depression "PROMIS Depression Scale"
  • Anxiety "PROMIS Anxiety Scale"
  • Fatigue "PROMIS Fatigue Scale"
  • Blood pressure "HUSH Sleep Diary"
  • Hypnotic use "Health Care Utilization Questionnaire" "HUSH Sleep Diary"
  • Health care costs "Health Care Utilization Questionnaire"
  • Side effects "Treatment-related Side Effects Scale"

研究の種類

介入

入学 (実際)

542

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Pennsylvania
      • Pittsburgh、Pennsylvania、アメリカ、15213
        • UPMC Health System

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~100年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Hypertension diagnosis 'Hypertension diagnosis' is indicated by the presence of at least one of the following:

    1. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis of essential hypertension in the electronic health record;
    2. Hypertension listed in the medical problem list in the electronic health record.
  2. At least one of the following:

    1. Hypnotic on active med list
    2. Insomnia on diagnosis or problem list
  3. Age 18 years and up.
  4. Meets criteria for DSM-5 (Diagnostic and Statistical Manual of Mental Disorders-5th ed.) Insomnia Disorder
  5. At least moderate insomnia severity: Score > 7 on Insomnia Severity Index
  6. Telephone, e-mail address, reliable Internet access. 'Reliable internet access' is defined by an individual having a personal e-mail address and having regular internet access within his/her own residence.
  7. Stable medical, psychiatric condition

Exclusion Criteria:

  1. Untreated current major depression (Patient Health Questionnaire (PHQ-9) score equal to or greater than 15; Generalized Anxiety Disorder (GAD-7) score > 10); patients using stable (3 mos) medication, psychological treatment ARE eligible
  2. History of bipolar disorder or psychosis
  3. Substance use disorder within past 3 months
  4. Dementia or probable dementia diagnosis
  5. Active suicidal ideation or psychosis
  6. Delayed sleep phase disorder (DSPD) or severe, untreated restless legs syndrome (RLS)
  7. Plans to leave present source of care during the following year
  8. Non-English speaking, illiterate, or sensory deficits
  9. Shift work that includes working the night shift (between the hours of 12:00 a.m. - 6:00 a.m.)
  10. Apnea Hypopnea Index (AHI) greater than or equal to 50 or O2 saturation 85% or less for > or = to 10% of the night.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:独身

武器と介入

参加者グループ / アーム
介入・治療
実験的:Brief Behavioral Treatment for Insomnia
Brief Behavioral Treatment for Insomnia (BBTI) employs behavioral strategies for managing insomnia and is administered in 4 brief weekly contacts with a therapist via online web conferencing.
BBTI employs behavioral strategies for treating insomnia, including stimulus control and sleep restriction. The BBTI interventionist contacts occur by telephone or web conferencing. It is administered in an initial session, followed by 3 brief weekly contacts, each guided by a printed workbook. During an initial 60 minute session, the sleep interventionist will review the participant's insomnia symptoms, discuss sleep regulation, and develop an individualized prescription of sleep wake times.
他の名前:
  • BBTI
実験的:Sleep Healthy Using the Internet (SHUTi)
SHUTi is an automated, interactive, personalized web-based program for improving insomnia through the use of Cognitive-Behavioral Therapy strategies for insomnia.
SHUTi is a self-guided, automated, interactive, and tailored web-based program modeled on the primary tenets of Cognitive Behavioral Treatment for Insomnia (CBT-I): sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention. Intervention content is metered out over 6 Cores based on a time and event-based schedule. SHUTi uses online sleep diaries to track progress and to tailor treatment (e.g., assign a "sleep restriction" window). Each Core acts as an online analog for the weekly sessions of traditional CBT-I and follows the same structure.
他の名前:
  • シュティ
プラセボコンパレーター:Enhanced Usual Care (EUC)
EUC involves the primary care physician's current treatment; feedback to patients and providers on assessment and treatment recommendations; an educational video from Emmi Solutions, Inc.
Participants randomized to EUC will complete the standard panel of self-report assessments and home blood pressure monitoring at baseline. The study team will generate an individualized report based, which will be sent to the participant and physician. The report will also contain publically-available educational resources (websites, books) and contact information for treatment resources. Participants in EUC will be given a link to a website containing an educational video on insomnia and its treatment, produced by Emmi Solutions, Inc. Participants in EUC will complete outcome assessments on the same schedule as participants in the other conditions. Participants who complete the EUC intervention will be offered the CBT-I/ SHUTi intervention following study completion.
他の名前:
  • EUC

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Sleep Disturbance
時間枠:9 weeks

Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance:

PROMIS Sleep Disturbance measures self-reported sleep quality and associated daytime functioning during the past seven days. It is administered by computerized adaptive testing (CAT) with individual responses guiding the system's choice of subsequent items from the full 27-item item bank.

Scale Range: Item responses are combined to yield a T-score with population mean of 50, standard deviation of 10, and range of ~20 - ~80. Higher scores indicate greater Sleep Disturbance.

9 weeks

二次結果の測定

結果測定
メジャーの説明
時間枠
Depression
時間枠:9 weeks, 6 months, 12 months

The PROMIS Depression Scale is a self-report measure that assesses negative mood, views of self, social cognition, affect and engagement during the past seven days. It is administered by computerized adaptive testing (CAT) with individual responses guiding the system's choice of subsequent items from the full 28-item bank.

Scale Range: Item responses are combined to yield a T-score with population mean of 50, standard deviation of 10, and range of ~20 - ~80. Higher scores indicate greater Depression.

9 weeks, 6 months, 12 months
Anxiety
時間枠:9 weeks, 6 months, 12 months

The PROMIS Anxiety Scale is a self-report measure that assesses fear, anxiousness, and hyperarousal and its associated somatic symptoms during the past seven days. It is administered by computerized adaptive testing (CAT) with individual responses guiding the system's choice of subsequent items from the full 29-item bank.

Scale Range: Item responses are combined to yield a T-score with population mean of 50, standard deviation of 10, and range of ~20 - ~80. Higher scores indicate greater Anxiety.

9 weeks, 6 months, 12 months
Fatigue
時間枠:9 weeks, 6 months, 12 months

The PROMIS Fatigue Scale is a self-report measure that assesses the experience and impact of fatigue during the past seven days. It is administered by computerized adaptive testing (CAT) with individual responses guiding the system's choice of subsequent items from the full 95-item bank.

Scale Range: Item responses are combined to yield a T-score with population mean of 50, standard deviation of 10, and range of ~20 - ~80. Higher scores indicate greater Fatigue.

9 weeks, 6 months, 12 months
Blood Pressure
時間枠:9 weeks, 6 months, 12 months

Home blood pressures are measured with an Omron BP786 home blood pressure monitor. Reported values for each day in each participant represent the average systolic and diastolic readings and heart rate from 3 measurements. Participants record these values in a 7-day sleep diary. Daily measurements for each participant are averaged across the number of days of recording.

Scale Range: Systolic BP range: 0 - 299; Diastolic BP range: 0 - 299; Heart rate range: 40 - 180. These values represent the reliable ranges for the device. For each variable, higher values are generally considered "worse" and lower values "better." However, very low values (e.g., systolic BP values <80, diastolic BP values <60, and HR values <50) may also indicate poor cardiovascular health.

9 weeks, 6 months, 12 months
Hypnotic Use
時間枠:9 weeks, 6 months, 12 months

Daily hypnotic use is self-reported in a 7-day sleep diary, with the ability to report up to 3 medications taken on a given night.

Scale Range: 22 Minimum Score: 0 (no hypnotic medication use on any day; better) Maximum Score: 21 (multiple hypnotic medications and/or multiple days of use; worse).

Retrospective hypnotic use in past 3 months is self-reported in a demographic and health care utilization questionnaire.

Scale Range: 0 - no limit Minimum Score: 0 (better) Maximum Score: no limit (multiple hypnotic medications and/or multiple days of use; worse).

9 weeks, 6 months, 12 months
Health Care Utilization
時間枠:9 weeks, 6 months, 12 months

The Health care utilization Questionnaire is a self-report measure that asks about recent health care services that have been sought and medications for hypertension and insomnia.

Scale Range: 0 - no limit Minimum Score: 0 (no visits or medications; better) Maximum Score: no limit (multiple visits and/or medications; worse)

9 weeks, 6 months, 12 months
Health-Related Quality of Life
時間枠:9 weeks, 6 months, 12 months

The Rand-12 is a 12-item self-report measure that produces physical health (PHC) and mental health (MHC) component scores. T-scores are used and have a population mean of 50.

Scale Range (PHC and MHC): 100 Minimum Score (PHC and MHC) = 0 (worse) Maximum Score (PHC and MHC) = 100 (better)

9 weeks, 6 months, 12 months
Client Satisfaction
時間枠:9 weeks

The Client Satisfaction Questionnaire (CSQ) is an 8-item self-report measure that assesses client satisfaction with the services they received.

Scale Range: 24 Minimum Score = 8 (low satisfaction) Maximum Score = 32 (high satisfaction)

9 weeks
Provider Satisfaction
時間枠:Following closing of recruitment

The provider satisfaction questionnaire is a self-report measure that assesses provider's perceived efficacy of the treatments their patients received, barriers to treatment, and satisfaction of both providers and patients.

Scale Range: 38 Minimum Score: 0 (low satisfaction) Maximum Score: 37 (high satisfaction)

Following closing of recruitment

その他の成果指標

結果測定
メジャーの説明
時間枠
Daytime Impairment Related to Sleep
時間枠:9 weeks, 6 months, 12 months

PROMIS Sleep Related Impairment is a self-report measure that assesses problems related to insufficient sleep during the past 7 days. It is administered by computerized adaptive testing (CAT) with individual responses guiding the system's choice of subsequent items from the full 16-item bank.

Scale Range: Item responses are combined to yield a T-score with population mean of 50, standard deviation of 10, and range of ~20 - ~80. Higher scores indicate greater sleep related impairment.

9 weeks, 6 months, 12 months
Side Effects
時間枠:9 weeks, 6 months, 12 months

Side effects (frequency, severity, impairment) are recorded via a self-report that was adapted from the Fisber.

Range: 22 Minimum Score: 0 (no side effects; better) Maximum Score: 21 (worse)

Those reporting severity of > moderate and/or frequency > 50% of the time in their self-report, or who spontaneously report a side effect, are contacted by the study coordinator. Information is gathered regarding the nature and duration of the event and action taken. Determination of causality and outcomes attributed to the event are then made.

9 weeks, 6 months, 12 months
Insomnia Severity
時間枠:9 weeks, 6 months, 12 months

The Insomnia Severity Index (ISI) is a 7-item self-report questionnaire that measures severity of insomnia symptoms during the last two weeks.

Scale Range: Minimum Score = 0 (no insomnia); Maximum Score = 28 (severe insomnia)

9 weeks, 6 months, 12 months
Sleep Quality
時間枠:9 weeks, 6 months, 12 months

The Pittsburgh Sleep Quality Index (PSQI) is an 18-item self-report measure that assesses sleep quality in the past month. These items are combined into seven component scores (subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbance, use of sleep medication, and daytime dysfunction). The seven component scores are added to produce a global sleep quality score. Higher global scores reflect lower sleep quality, with 5 as a cut-off distinguishing good from poor sleepers.

Scale Range: 22

Minimum Score = 0 (better); Maximum Score = 21 (worse)

9 weeks, 6 months, 12 months
Daytime Sleepiness
時間枠:9 weeks, 6 months, 12 months

The Epworth Sleepiness Scale (ESS) is an 8-item self-report measure that assesses daytime sleepiness by asking about the likelihood of dozing in certain situations. Individual items are summed to yield the ESS score.

Scale Range: 25

Minimum Score = 0 (never doze); Maximum Score = 24 (doze a lot)

9 weeks, 6 months, 12 months
Falls
時間枠:9 weeks, 6 months, 12 months

Falls are recorded via self-report.

Range: 5 Minimum Score: 0 (no falls; better) Maximum Score: 5 (> 4 falls; worse)

Those reporting a fall are contacted by the coordinator and information is gathered regarding the date and time of day of the fall(s), proximity to a sleep episode, contributing factors, and whether or not medication for sleep or anxiety were taken in the 24 hours preceding the fall.

9 weeks, 6 months, 12 months
Improvement
時間枠:9 weeks, 6 months, 12 months

The Patient Global Impression of Improvement (PGI-I) Scale is a self-report measure that rates perceived response to intervention.

Scale Range: 7 Minimum Score: 1 (very much improved; better) Maximum Score: 7 (very much worse; worse)

9 weeks, 6 months, 12 months
Bed times
時間枠:Intervention, 9 weeks, 6 months, 12 months

The in and out of bed times are recorded in a 7-day sleep diary and include: bed time, lights out time, wake time, and out-of-bed time. Bed time is the clock time when the participant got into bed. Lights out time is the clock time when the participant actually attempted to sleep (i.e., turned out the lights). Wake time is the clock time of the participant's final awakening. Out-of-bed time is the clock time they got out of bed for the day.

Ranges for these clock-time variables use 24 hours, with no minimum or maximum value.

Intervention, 9 weeks, 6 months, 12 months
Time to fall asleep
時間枠:Intervention, 9 weeks, 6 months, 12 months

Time to fall asleep is recorded in a 7-day sleep diary.

Range: 24 hours Minimum value = 0 minutes (better) Maximum value = 1440 minutes (worse)

Intervention, 9 weeks, 6 months, 12 months
Wake After Sleep Onset (WASO)
時間枠:Intervention, 9 weeks, 6 months, 12 months

WASO is recorded in a 7-day sleep diary, and refers to the number of minutes of wakefulness between the time of falling asleep and Wake Time.

Range: 24 hours Minimum value = 0 minutes (better) Maximum value = 1440 minutes (worse)

Intervention, 9 weeks, 6 months, 12 months
Subjective Sleep Quality
時間枠:Intervention, 9 weeks, 6 months, 12 months

Subjective sleep quality is recorded in a 7-day sleep diary.

Range: 5 Minimum score: 0 (very poor; worse) Maximum score: 4 (very good; better)

Intervention, 9 weeks, 6 months, 12 months
Use of Sleep Medication
時間枠:Intervention, 9 weeks, 6 months, 12 months

Use of sleep medication is recorded in a 7-day sleep diary, with the ability to report up to 3 medications taken on a given night.

Scale Range: 22

Minimum Score: 0 (no sleep medication use on any night; better) Maximum Score: 21 (multiple sleep medications and/or multiple nights of use; worse).

Intervention, 9 weeks, 6 months, 12 months
Sleep Efficiency
時間枠:Intervention, 9 weeks, 6 months, 12 months

Sleep Efficiency is calculated from values recorded in a 7-day sleep diary. It refers to the percentage of time asleep while in bed. Time in bed is calculated as (Out of bed time) - (Bed time), in minutes. Sleep efficiency is calculated as (Total sleep time/time in bed) X 100.

Range: 101 Minimum for sleep efficiency: 0% (worse) Maximum for sleep efficiency: 100% (better)

Intervention, 9 weeks, 6 months, 12 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Daniel J Buysse, MD、University of Pittsburgh

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始

2015年8月1日

一次修了 (実際)

2020年3月5日

研究の完了 (実際)

2020年3月5日

試験登録日

最初に提出

2015年7月21日

QC基準を満たした最初の提出物

2015年7月22日

最初の投稿 (見積もり)

2015年7月24日

学習記録の更新

投稿された最後の更新 (実際)

2020年9月3日

QC基準を満たした最後の更新が送信されました

2020年9月1日

最終確認日

2020年9月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

We will make available to the research community any resource that is presented in a publication that is published or accepted for publication. We agree to release and share data in a timely manner, but no later than one year following completion of the funded project period or the date of publication of the main findings from our final data set.

Data will be provided in the form of an Access data base.

A data dictionary will be provided to define all data fields.

We will not provide data analytic tools.

We are providing this Data Sharing Agreement in keeping with the requirements of RFA-HL-14-019.

Data will be shared as Access data base(s), provided in electronic format by e-mail or durable media.

IPD 共有時間枠

We agree to release and share data in a timely manner, but no later than one year following completion of the funded project period or the date of publication of the main findings from our final data set.

IPD 共有アクセス基準

We will share data with investigators working at an institution with a Federal Wide Assurance.

To gain access to data, researchers must submit a detailed description of their project. The proposal must include the investigator's personal identification and institutional affiliation, a current CV, qualifications, estimated duration of the proposed research, source of financial support, and a conflict of interest statement. The protocol described must include study aims, background and significance, and methods and types of analysis, and a description of the data requested and list of variables. Once approved, the investigator must complete the necessary University of Pittsburgh IRB exempt research application form and document completion of a responsible conduct of research program. Data will be prepared by an 'honest broker.' Data will not be provided that could identify individual research participants or that the original consent form expressly forbade.

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する